The effect of cachexia-inducing lung tumor-conditioned medium on the therapeutic potential of human mesoangioblasts
While human mesoangioblasts show potential to treat lung cancer-induced cachexia, their therapeutic efficacy may be compromised by cisplatin chemotherapy and specific tumor-secreted factors that temporarily halt muscle differentiation, though this blockage is reversible upon removal of the inhibitory medium.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
When a person develops advanced lung cancer, the body often begins a destructive process known as cachexia. This is not simply a loss of appetite or weight; it is a complex metabolic disorder where the body actively breaks down its own skeletal muscle and fat tissue, even if the person continues to eat. For patients, this muscle wasting is devastating. It weakens them physically, making it harder to tolerate standard cancer treatments, and it significantly increases the risk of death. Currently, there is no effective cure for this condition. Medical science has long searched for ways to stop this muscle loss or rebuild the tissue that has been destroyed, but the environment created by a tumor makes this task incredibly difficult.
Researchers are exploring a promising approach using mesoangioblasts, a specific type of stem cell found in the walls of blood vessels. These cells have a unique ability: if injected into the bloodstream, they can travel to damaged muscles, settle in, and transform into new muscle fibers. In previous studies involving muscular dystrophy, these cells showed great potential for repairing muscle. However, before doctors could consider using them to treat cancer-related muscle wasting, they needed to know if the cells could survive the harsh conditions of a cancer patient. Specifically, they had to determine if the chemotherapy drugs used to kill the tumor would also kill the stem cells, and if the toxic signals released by the tumor itself would stop the stem cells from doing their job.
A team of scientists at Maastricht University Medical Centre set out to answer these questions. They began by testing how human mesoangioblasts reacted to two common chemotherapy drugs used for lung cancer: etoposide and cisplatin. They exposed the stem cells to these drugs and compared their survival rates to those of lung cancer cells and healthy lung cells. The results showed a clear difference in how the cells handled the treatment. The stem cells were significantly more resistant to etoposide than the cancer cells were, meaning the drug could kill the tumor without wiping out the stem cells. However, the stem cells were just as sensitive to cisplatin as the cancer cells were. This finding suggests that while stem cell therapy is possible, doctors would need to be very careful about which chemotherapy drugs they use, or perhaps find ways to protect the stem cells from the specific drugs that harm them.
Next, the researchers investigated the invisible chemical battlefield created by the tumor. Tumors release a constant stream of proteins and signaling molecules into the body, which can alter how other cells behave. To study this, the team grew three different types of lung cancer cells in a dish. One type caused no muscle wasting in mice, one caused mild wasting, and the third caused severe wasting. They collected the liquid surrounding these cells, known as conditioned media, which contained all the factors secreted by the tumors. They then bathed the human mesoangioblasts in this liquid to see if the tumor's chemical signals would stop the stem cells from growing, moving, or turning into muscle.
The study revealed that the tumor secretions did not stop the stem cells from multiplying or moving. The mesoangioblasts were able to grow and migrate through layers of blood vessel cells just as well in the presence of the tumor liquid as they did in normal conditions. This is a crucial finding because it means the stem cells can likely reach the damaged muscles even when a tumor is present. However, the story changed when the researchers asked the stem cells to start building new muscle. When exposed to the liquid from the tumor that caused severe muscle wasting, the stem cells lost their ability to differentiate, or transform, into mature muscle fibers. Their development halted, and they failed to produce the key proteins needed to form strong muscle tissue. The liquid from the tumors that caused mild or no wasting did not have this blocking effect.
The researchers then tested whether this blockage was permanent. They exposed the stem cells to the severe tumor liquid for four days and then switched them back to normal, healthy growth liquid. The stem cells were able to recover. After the switch, they began to produce muscle proteins again, and their ability to form muscle fibers returned to near-normal levels. This suggests that the tumor does not destroy the stem cells' potential; it merely pauses their development. As long as the inhibitory signal is removed, the cells can resume their work.
These findings offer a cautious but hopeful path forward for treating cancer cachexia. The study demonstrates that mesoangioblasts are robust enough to survive chemotherapy and navigate the body to reach muscles, even in the presence of a tumor. The main obstacle is the tumor's ability to temporarily freeze the stem cells' ability to turn into muscle, but this freeze appears to be reversible. While the researchers did not identify the exact chemical responsible for this block, their work proves that the concept of using these stem cells to fight muscle wasting is viable. It suggests that with the right combination of chemotherapy and perhaps a strategy to overcome the tumor's inhibitory signals, it may one day be possible to restore muscle mass in patients who are currently losing it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.